BMRA - Biomerica, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.23
-0.03 (-0.70%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.37
Open4.22
Bid4.16 x 100
Ask4.85 x 300
Day's Range4.10 - 4.30
52 Week Range2.69 - 9.32
Volume37,974
Avg. Volume89,008
Market Cap36.08M
Beta-0.72
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Trade prices are not sourced from all markets
  • Biomerica, Inc. :BMRA-US: Earnings Analysis: Q2, 2018 By the Numbers : January 19, 2018
    Capital Cube6 hours ago

    Biomerica, Inc. :BMRA-US: Earnings Analysis: Q2, 2018 By the Numbers : January 19, 2018

    Categories: Yahoo FinanceGet free summary analysis Biomerica, Inc. reports financial results for the quarter ended November 29, 2017. Highlights Summary numbers: Revenues of USD 1.61 million, Net Earnings of USD -0.27 million. Gross margins narrowed from 38.87% to 31.37% compared to the same period last year, operating (EBITDA) margins now -15.09% from -11.28%. Change in operating cash ... Read more (Read more...)

  • GlobeNewswire3 days ago

    Biomerica Announces Second Quarter Financial Results; Sales Up 12.7% for the Quarter

    IRVINE, Calif., Jan. 16, 2018-- Biomerica, Inc. today reported net sales of $1,613,636 for the three months ended November 30, 2017, compared to $1,432,206 for the same period in the previous year, an ...

  • GlobeNewswire9 days ago

    China Food and Drug Administration (CFDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer

    IRVINE, Calif., Jan. 10, 2018-- Biomerica, Inc. announced the China Food and Drug Administration approval of the EZ Detect™ colorectal screening test designed to help identify the early warning signs of ...

  • Biomerica Inc (NASDAQ:BMRA): Poised For Long-Term Success?
    Simply Wall St.10 days ago

    Biomerica Inc (NASDAQ:BMRA): Poised For Long-Term Success?

    Biomerica Inc’s (NASDAQ:BMRA) most recent earnings update in August 2017 revealed company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Investors mayRead More...

  • GlobeNewswire11 days ago

    Biomerica Signs Agreements with Beth Israel Deaconess & University of Michigan to Initiate Clinical Study for First of a Kind, Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy (DGT)

    -DGT Designed to identify patient specific foods, that when removed, may alleviate an individual's IBS symptoms. -DGT can be used alongside current IBS drug treatments to potentially improve outcomes. ...

  • Is Biomerica Inc (NASDAQ:BMRA) Thriving Or Barely Surviving In The Healthcare Sector?
    Simply Wall St.18 days ago

    Is Biomerica Inc (NASDAQ:BMRA) Thriving Or Barely Surviving In The Healthcare Sector?

    Biomerica Inc (NASDAQ:BMRA), a USD$31.90M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and the growingRead More...

  • Does Biomerica Inc’s (NASDAQ:BMRA) Earnings Growth Make It An Outperformer?
    Simply Wall St.25 days ago

    Does Biomerica Inc’s (NASDAQ:BMRA) Earnings Growth Make It An Outperformer?

    Measuring Biomerica Inc’s (NASDAQ:BMRA) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations,Read More...

  • What You Must Know About Biomerica Inc’s (BMRA) Financial Health
    Simply Wall St.last month

    What You Must Know About Biomerica Inc’s (BMRA) Financial Health

    The direct benefit for Biomerica Inc (NASDAQ:BMRA), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off isRead More...

  • ACCESSWIRE2 months ago

    Biomerica Announces Enrollment of First Patient for H. Pylori Clinical Studies at the University of Southern California

    IRVINE, CA / ACCESSWIRE / November 20, 2017 / Biomerica Inc. (NASDAQ: BMRA ) today announced the enrollment of its first patient at the University of Southern California for the Company's Helicobacter ...

  • Who Are The Major Shareholders In Biomerica Inc (BMRA)?
    Simply Wall St.2 months ago

    Who Are The Major Shareholders In Biomerica Inc (BMRA)?

    In this analysis, my focus will be on developing a perspective on Biomerica Inc’s (NASDAQ:BMRA) latest ownership structure, a less discussed, but important factor. Ownership structure of a company hasRead More...

  • Zacks Small Cap Research3 months ago

    BMRA: Q1 Results Solid. H. Pylori Test Piques Interest

    By Brian Marckx, CFA NASDAQ:BMRA Q1 2018 Results: Fairly Solid, Timing Issue Should Benefit Q2. Looking Forward to Details on H. Pylori Test...  Biomerica (NASDAQ:BMRA) reported financial results for their ...

  • Biomerica, Inc. :BMRA-US: Earnings Analysis: Q1, 2018 By the Numbers : October 17, 2017
    Capital Cube3 months ago

    Biomerica, Inc. :BMRA-US: Earnings Analysis: Q1, 2018 By the Numbers : October 17, 2017

    Categories: Yahoo FinanceGet free summary analysis Biomerica, Inc. reports financial results for the quarter ended August 31, 2017. Highlights Summary numbers: Revenues of USD 1.44 million, Net Earnings of USD -0.35 million. Gross margins narrowed from 40.92% to 35.62% compared to the same period last year, operating (EBITDA) margins now -12.27% from -0.90%. Change in operating cash ... Read more (Read more...)

  • ACCESSWIRE4 months ago

    Analyst Sees 35% Upside in Shares of Biomerica, Inc.

    NEW YORK, NY / ACCESSWIRE / September 20, 2017 / Zacks Small-Cap Research (''Zacks''), a leading provider of investment information and stock research reports, has recently published an in-depth report ...

  • Zacks Small Cap Research4 months ago

    BMRA Looking To Capitalize On Strong OUS Growth With Expanded Distribution

    By Brian Marckx, CFA NASDAQ:BMRA Q4 2017 Results:  Looking To Capitalize On Strong OUS Growth With Expanded Distribution..  Biomerica (NASDAQ:BMRA) reported financial results for their fiscal fourth quarter ...

  • Biomerica, Inc. :BMRA-US: Earnings Analysis: Q4, 2017 By the Numbers : August 31, 2017
    Capital Cube5 months ago

    Biomerica, Inc. :BMRA-US: Earnings Analysis: Q4, 2017 By the Numbers : August 31, 2017

    Categories: Yahoo FinanceGet free summary analysis Biomerica, Inc. reports financial results for the quarter ended May 31, 2017. We analyze the earnings along side the following peers of Biomerica, Inc. – DENTSPLY SIRONA, Inc., Align Technology, Inc., BIOLASE, Inc. and Milestone Scientific Inc. (XRAY-US, ALGN-US, BIOL-US and MLSS-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)

  • Marketwired8 months ago

    Biomerica to present at the 18th Annual B. Riley & Co. investor conference on May 24, 2017

    Biomerica Inc. today announced it will present at the 18th Annual B. Riley institutional investor conference being held May 24-25, 2017 in Santa Monica, CA.Zackary Irani, Chief Executive Officer of Biomerica, ...

  • Zacks Small Cap Research9 months ago

    BMRA: Base Business Bouncing Back With Three Quarters of Sequential Growth

    Revenue from Asia was $448k, up 22% from $367k in Q3 2016 (i.e. Europe has not been nearly as positive which saw sales fall 20% in fiscal 2016 and shed another 7% through the first half of fiscal 2017.  But while one quarter does not make a trend, the most recent period bucked the prior 18-months of disappointing sales.  Q3 ’17 European revenue of $654k was 20% better than the prior year number, up 41% from Q2 and the highest since Q4 2015.  While Biomerica has never provided much in the way of detailed trends effecting revenue, they do note in the Q3 10-Q that an increase in sales of clinical laboratory products benefitted both their Asian and European segments.  As we noted in previous updates, we viewed recent signs of European revenue stabilizing around ~$500k/quarter as encouraging relative to the potential for this territory to return to positive growth in the coming (i.e.

  • Capital Cube9 months ago

    Biomerica, Inc. :BMRA-US: Earnings Analysis: Q3, 2017 By the Numbers : April 18, 2017

    Categories: Yahoo FinanceGet free summary analysis Biomerica, Inc. reports financial results for the quarter ended February 28, 2017. Highlights Summary numbers: Revenues of USD 1.50 million, Net Earnings of USD -0.30 million. Gross margins widened from 25.30% to 29.96% compared to the same period last year, operating (EBITDA) margins now -17.68% from -15.49%. Change in operating cash ... Read more (Read more...)

  • Marketwired9 months ago

    Biomerica Announces Third Quarter Financial Results, Sales up 13.9% for Nine Months

    Biomerica, Inc. today reported net sales of $4,342,247 for the nine months ending February 28, 2017, compared to $3,813,683 for the period ended February 29, 2016. Sales for the three months ending February ...

  • Marketwired10 months ago

    Biomerica to present at the 29th Annual ROTH conference on March 13, 2017

    Biomerica Inc. today announced it will present at the 29th Annual ROTH Conference being held March 12-15, 2017 in Dana Point, CA.Zackary Irani, Chief Executive Officer of Biomerica, will present a business ...

  • Zacks Small Cap Researchlast year

    BMRA: Analysis of IBS Drugs Indicates Unmet Need for Alternative Therapies

    Biomerica (BMRA) reported financial results for their fiscal second quarter ending November 30.  Revenue, for the second straight quarter, surprised on the upside by about 12% relative to our estimate with the majority of the beat in both periods related to stronger than anticipated sales in Asia.  Similarly, it wasn’t just revenue that impressed, gross margin also came in much wider than we modeled – again for the second straight quarter. Q2 revenue of $1.4M was up 23% yoy, up 2% sequentially and about 12% better than our $1.3M estimate.  It was also the highest since fiscal Q4 2015 (May 2015).  While revenue in both Europe and the U.S., which account for approximately 35% and 15% of total revenue, respectively, saw revenue decline on both a yoy and sequential basis, this was more than offset by relatively very strong sales in Asia, which accounts for ~45% of total revenue.